Use of idarucizumab in reversing dabigatran anticoagulant effect: a critical appraisal

Figures & data

Table 1 Main characteristics of idarucizumab

Feature	Idarucizumab
Structure	Humanized Fab fragment
Molecular mechanism	Noncompetitive binding (350-fold higher affinity than thrombin)
Route of delivery	Two 50-mL intravenous bolus infusions 15 minutes apart, equal to 5 g of drug
Regulatory aspects	Approved by FDA and EMA
Latency	Immediate onset of reversal
Duration of effect	12–24 hours
Studies	NCT01688830,^Citation7 NCT02104947 (REVERSE-AD)^Citation8,Citation9
Costs	$3,662.06 (US) – €3,909.91 (EU) per unit

Abbreviations: EMA, European Medicines Agency; FDA, Food and Drug Administration.

Figure 1 Idarucizumab and dabigatran in the context of the hemostatic process.

GlundSStangierJSchmohlMSafety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trialLancet2015386999468069026088268

 PubMed Web of Science ®Google Scholar

PollackCVReillyPAEikelboomJIdarucizumab for dabigatran reversalN Engl J Med Overseas Ed20153736511520

 PubMed Web of Science ®Google Scholar

PollackCVReillyPAvan RynJIdarucizumab for dabigatran reversal – full cohort analysisN Engl J Med2017377543144128693366

 PubMed Web of Science ®Google Scholar